Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retinoid X receptor suppresses transformation by the v-myb oncogene.
Smarda J, Zemanová K, Bryja J, Smardová J, Kozubík A, Hofmanová J, Nemajerová A, Sevcíková S, Kohoutek J, Vodicka P. Smarda J, et al. Among authors: sevcikova s. J Leukoc Biol. 1999 Dec;66(6):1039-48. doi: 10.1002/jlb.66.6.1039. J Leukoc Biol. 1999. PMID: 10614788
Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
Almasi M, Sevcikova S, Slaby O, Kaisarova P, Maisnar V, Penka M, Pika T, Pour L, Radocha J, Scudla V, Svachova H, Hajek R. Almasi M, et al. Among authors: sevcikova s. Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):414-20. doi: 10.1016/j.clml.2011.03.024. Epub 2011 May 10. Clin Lymphoma Myeloma Leuk. 2011. PMID: 21859556
Genomics in multiple myeloma research.
Sevcíková S, Nemec P, Pour L, Hájek R. Sevcíková S, et al. Klin Onkol. 2011;24 Suppl:S34-8. Klin Onkol. 2011. PMID: 21923062
Mechanism of immunomodulatory drugs in multiple myeloma.
Sedlarikova L, Kubiczkova L, Sevcikova S, Hajek R. Sedlarikova L, et al. Among authors: sevcikova s. Leuk Res. 2012 Oct;36(10):1218-24. doi: 10.1016/j.leukres.2012.05.010. Epub 2012 Jun 21. Leuk Res. 2012. PMID: 22727252 Review.
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Smetana J, Berankova K, Zaoralova R, Nemec P, Greslikova H, Kupska R, Mikulasova A, Frohlich J, Sevcikova S, Zahradova L, Krejci M, Sandecka V, Almasi M, Kaisarova P, Melicharova H, Adam Z, Penka M, Jarkovsky J, Jurczyszyn A, Hajek R, Kuglik P. Smetana J, et al. Among authors: sevcikova s. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):123-30. doi: 10.1016/j.clml.2012.11.012. Epub 2013 Jan 4. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23291040
120 results